Peringatan Keamanan

Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing

Hydrocortisone valerate

DB14544

small molecule approved vet_approved

Deskripsi

Struktur Molekul 2D

Berat 446.5763
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 6-8 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Metabolisme

Primarily hepatic via CYP3A4

Rute Eliminasi

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Interaksi Obat

172 Data
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Hydrocortisone valerate.
Tacrolimus Tacrolimus may increase the immunosuppressive activities of Hydrocortisone valerate.
Segesterone acetate The metabolism of Segesterone acetate can be increased when combined with Hydrocortisone valerate.
Phenylephrine The risk or severity of hypertension can be increased when Hydrocortisone valerate is combined with Phenylephrine.
Aminoglutethimide The therapeutic efficacy of Hydrocortisone valerate can be decreased when used in combination with Aminoglutethimide.
Insulin human The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin human.
Insulin lispro The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin lispro.
Insulin glargine The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin glargine.
Insulin pork The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin pork.
Troglitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Troglitazone.
Glimepiride The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Glimepiride.
Sulfisoxazole The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Sulfisoxazole.
Disopyramide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Disopyramide.
Acarbose The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Acarbose.
Metformin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Metformin.
Sulfadiazine The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Sulfadiazine.
Rosiglitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Rosiglitazone.
Acetohexamide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Acetohexamide.
Quinine The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Quinine.
Miglitol The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Miglitol.
Chlorpropamide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Chlorpropamide.
Nateglinide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Nateglinide.
Pentamidine The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Pentamidine.
Mifepristone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Mifepristone.
Tolazamide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Tolazamide.
Repaglinide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Repaglinide.
Phenformin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Phenformin.
Sulfamethoxazole The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Sulfamethoxazole.
Glyburide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Glyburide.
Glipizide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Glipizide.
Gliclazide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Gliclazide.
Tolbutamide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Tolbutamide.
Bromocriptine The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Bromocriptine.
Gliquidone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Gliquidone.
Mitiglinide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Mitiglinide.
Sitagliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Sitagliptin.
Sunitinib The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Sunitinib.
Exenatide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Exenatide.
Mecasermin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Mecasermin.
Pramlintide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Pramlintide.
Glisoxepide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Glisoxepide.
Insulin aspart The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin aspart.
Insulin detemir The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin detemir.
Insulin glulisine The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin glulisine.
Glymidine The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Glymidine.
AICA ribonucleotide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with AICA ribonucleotide.
Buformin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Buformin.
Vildagliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Vildagliptin.
Voglibose The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Voglibose.
NN344 The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with NN344.
AMG-222 The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with AMG-222.
Bisegliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Bisegliptin.
Alogliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Alogliptin.
Dapagliflozin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Dapagliflozin.
Saxagliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Saxagliptin.
Liraglutide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Liraglutide.
Gosogliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Gosogliptin.
Linagliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Linagliptin.
Canagliflozin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Canagliflozin.
Glibornuride The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Glibornuride.
Benfluorex The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Benfluorex.
Empagliflozin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Empagliflozin.
Albiglutide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Albiglutide.
Dulaglutide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Dulaglutide.
Lobeglitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Lobeglitazone.
Netoglitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Netoglitazone.
Rivoglitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Rivoglitazone.
Ciglitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Ciglitazone.
Lixisenatide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Lixisenatide.
Insulin beef The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin beef.
Insulin degludec The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin degludec.
Insulin peglispro The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin tregopil.
Ipragliflozin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Ipragliflozin.
Dutogliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Dutogliptin.
Allicin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Allicin.
Tofogliflozin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Tofogliflozin.
Ertugliflozin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Ertugliflozin.
2,4-thiazolidinedione The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with 2,4-thiazolidinedione.
Teneligliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Teneligliptin.
Omarigliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Omarigliptin.
Carmegliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Carmegliptin.
Gemigliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Gemigliptin.
Anagliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Anagliptin.
Evogliptin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Evogliptin.
Sotagliflozin The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Sotagliflozin.
Balaglitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Balaglitazone.
Remogliflozin etabonate The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Remogliflozin etabonate.
Carbutamide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Carbutamide.
Guar gum The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Guar gum.
Metahexamide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Metahexamide.
Semaglutide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Semaglutide.
Taspoglutide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Taspoglutide.
Englitazone The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Englitazone.
Tirzepatide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Tirzepatide.
Gastric inhibitory polypeptide The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Gastric inhibitory polypeptide.
Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Hydrocortisone valerate.
Cyclosporine The risk or severity of adverse effects can be increased when Hydrocortisone valerate is combined with Cyclosporine.
Digoxin The risk or severity of adverse effects can be increased when Hydrocortisone valerate is combined with Digoxin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Hydrocortisone valerate is combined with Acetyldigitoxin.

Target Protein

Annexin A1 ANXA1
Glucocorticoid receptor NR3C1
11-beta-hydroxysteroid dehydrogenase type 2 HSD11B2
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 HSD3B1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 12932892
    de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52.
  • PMID: 6461917
    Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31.
  • PMID: 13233328
    KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81.

Contoh Produk & Brand

Produk: 26 • International brands: 0
Produk
  • Hydrocortisone Valerate
    Cream • 2 mg/1g • Topical • US • Generic • Approved
  • Hydrocortisone Valerate
    Ointment • 2 mg/1g • Topical • US • Generic • Approved
  • Hydrocortisone Valerate
    Cream • 2 mg/1g • Topical • US • Generic • Approved
  • Hydrocortisone Valerate
    Cream • 2 mg/1g • Topical • US • Generic • Approved
  • Hydrocortisone Valerate
    Cream • 2 mg/1g • Topical • US • Generic • Approved
  • Hydrocortisone valerate
    Cream • 2 mg/1g • Topical • US • Generic • Approved
  • Hydrocortisone Valerate
    Cream • 2 mg/1g • Topical • US • Generic • Approved
  • Hydrocortisone Valerate
    Cream • 2 mg/1g • Topical • US • Generic • Approved
Menampilkan 8 dari 26 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul